GPT and hepatocellular carcinoma: In a population of 1815 Caucasian adults with chronic hepatitis B and no HCC, who received treatment with entecavir or tenofovir for more than 12 months, an HCC risk prediction score was developed based on age, gender, HBeAg status, body mass index (BMI), ALT, platelet count, HBV viral load, prior treatment with interferon or nucleos(t)ide analogues other than entecavir/tenofovir, and the presence of cirrhosis.